AstraZeneca has revealed that its top executive in China, Leon Wang, has been detained by Chinese authorities, after ...

Chavez, MD, discusses the efficacy of immunotherapy for the potential treatment of extensive-stage small cell lung cancers.

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Astrazeneca (AZN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the ...

AstraZeneca's key medicines, mainly cancer drugs, Lynparza, Tagrisso and Imfinzi, and diabetes medicine Farxiga are expected ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

AstraZeneca PLC (OTCMKTS:AZNCF – Get Free Report) was the target of a large decrease in short interest during the month of October. As of October 15th, there was short interest totalling 37,100 shares ...

Arcus Biosciences has a promising pipeline with five Phase 3 trials focused on GI and NSCLC cancers. Learn why RCUS stock ...

An expert addressed the emerging role of immune checkpoint inhibitors in the perioperative space based on findings from the CheckMate 816, IMpower010, PEARLS, and ADAURA trials.

Dakota Wealth Management cut its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 1.8% in the 3rd quarter, ...

AstraZeneca's hopes of developing its PD-L1 inhibitor Imfinzi for cervical cancer have been hit by a failed phase 3 trial of the drug alongside chemotherapy as a first-line treatment for women ...

AstraZeneca, a global biopharmaceutical company that develops and commercializes prescription medicines, became a household ...